Oct 24, 2025
The chronic pruritus drugs market is currently not highly competitive, with only a few chronic pruritus drugs approved for treatment, including KORSUVA/KAPRUVIA (Cara Therapeutics/CSL/ Vifor/Maruishi), LIVMARLI (Mirum Pharmaceuticals/Takeda), and BYLVAY/KAYFANDA (Mirum Pharmaceuticals/Takeda). However, the treatmen...
Read More...
Oct 13, 2025
Chronic pruritus, characterized by itching that persists for more than six weeks, is a multifaceted condition that may stem from dermatologic, systemic, neurologic, or psychogenic factors. It has a profound impact on patients’ quality of life and is increasingly recognized as a standalone clinical entity. DelveInsi...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper